Crispr Therapeutics AG (CRSP)

[jondoeuk]

The company has expanded the CTX110 trial to incorporate consolidation dosing and begun treating patients in a pivotal arm. Also, top-line data is expected to be reported this half for the ongoing CTX120 and CTX130 (in ccRCC and T/B-cell malignancies) trials.

In addition, they have locked in the design and edits (four or five) for next-gen. Now, are designing third-gen, which will have seven or eight edits. Beyond that, with their own facility, have automated parts of manufacturing, are using machine learning plus translational data, as well as CRISPR screens. Preclinical data from last year https://aacrjournals.org/cancerres/article-abstract/81/13_Supplement/1537/667455/Abstract-1537-CD70-knockout-A-novel-approach-to